RADIOLABELLED ALPHA-V BETA-3 AND/OR ALPHA-V BETA-5 INTEGRINS ANTAGONIST FOR USE AS THERAGNOSTIC AGENT
The present disclosure relates to αvβ3 and/or αvβ5 integrins antagonist radiopharmaceuticals and their use in a theragnostic approach for selection and therapy of human subjects with tumors overexpressing αvβ3 and/or αvβ5 integrins. In particular, the present disclosure relates to a pharmaceutical c...
Saved in:
Main Authors | , , , , , , , |
---|---|
Format | Patent |
Language | English French German |
Published |
25.10.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present disclosure relates to αvβ3 and/or αvβ5 integrins antagonist radiopharmaceuticals and their use in a theragnostic approach for selection and therapy of human subjects with tumors overexpressing αvβ3 and/or αvβ5 integrins. In particular, the present disclosure relates to a pharmaceutical composition of αv 177Lu radiolabeled αvβ3 and/or αvβ5 integrins antagonist, for use in treating tumors overexpressing αvβ3 and/or αvβ5 integrins in a human subject eligible for said treatment, wherein said subject has been selected for the treatment by PET/CT or PET/MRI or SPECT/CT or SPECT/MRI imaging with the same αvβ3 and/or αvβ5 integrins antagonist but with 68-Ga as radiometal for use as imaging agent. |
---|---|
Bibliography: | Application Number: EP20210843691 |